Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (ATP)

  • End date
    Aug 15, 2028
  • participants needed
  • sponsor
    RenJi Hospital
Updated on 4 October 2022


This is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose is to investigate whether pyrotinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer based on the 1-year trastuzumab standard adjuvant treatment with or without pertuzumab.

Condition Locally Advanced Breast Cancer
Treatment Pyrotinib
Clinical Study IdentifierNCT04254263
SponsorRenJi Hospital
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Female, Aged ≥18 and ≤70 years
Histologically confirmed invasive HER2 positive breast cancer, early disease(Stage ⅡA-Ⅲ)
Completed neoadjuvant therapy, including chemotherapy and trastuzumab
Residual invasive disease was detected pathologically in the surgical specimen of the breast or axillary lymph nodes after completion of neoadjuvant chemotherapy
Been or being treated for early breast cancer with standard of care duration of trastuzumab
Adjuvant treatment regimen needs to be determined before randomization
Duration from Random time to the last use of trastuzumab≤1 year
Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1
Required laboratory values including following parameters:ANC: ≥ 1.5 x 109/L; Platelet count: ≥ 100 x 109/L; Hemoglobin: ≥ 9.0 g/dL; Total bilirubin: ≤ 1.5 x upper limit of normal, ULN; ALT and AST: ≤ 1.5 x ULN; BUN and creatine clearance rate: ≥ 50 mL/min; LVEF: ≥ 50%; QTcF: < 470 ms
Signed informed consent form (ICF)

Exclusion Criteria

Metastatic disease (Stage IV)
Gross residual disease remaining after mastectomy or positive margins after breast-conserving surgery
Progressive disease during neoadjuvant therapy
Subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption
Treated or treating with anti-HER2 TKI, including but not limited to pyrotinib, lapatinib and neratinib
Less than 4 weeks from the last clinical trial
History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation
Subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) Any heart diseases judged by investigator as unsuitable to participate in the trial
Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note